Literature DB >> 21174933

Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection.

Takafira Mduluza1, Francisca Mutapi, Tinashe Ruwona, Daniel Kaluka, Nicholas Midzi, Patricia D Ndhlovu.   

Abstract

The effect of treatment with either oxamniquine or praziquantel on S.mansoni specific IFN-gamma, IL-4, IL-5 and IL-10 was compared on PBMC which were collected pretreatment, 6 and 18 weeks post treatment. Using sandwich ELISA on the supernatants harvested from the PBMC stimulation by crude S. mansoni SEA and SWAP antigens after 5 days the levels of PBMC proliferation and cytokine production were similar according to treatment with either praziquantel or oxamniquine. Before treatment, infected groups showed low ratios, of IL-4:IFN-gamma, IL-5:IFNgamma and IL-10:IFN-gamma, indicating that IFN-gamma was high in the infected individuals. The general increase in immuno-modulation was observed post-treatment with elevated immune reactivity and cytokine production in both treatment groups. Treatment induced significant increases in levels of IL-4 (p < 0.05), IL-5 (p < 0.0001) and IL-10 (p < 0.05) cytokines 6 and 18 weeks after treatment. There were no significant differences in the increase in IL-4, IL-5 and IL-10 between children treated with praziquantel or oxamniquine. Pre-treatment IFN-gamma and IL-5 levels were positively correlated with infection (p < 0.001), while post treatment IL-4 cytokine levels were negatively correlated with baseline infection status (p < 0.001). The results suggest that treatment-induced immune responses are similar for both common anti-schistosome drugs praziquantel or oxamniquine having similar and immunizing effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 21174933      PMCID: PMC3345748          DOI: 10.4314/mmj.v21i4.49642

Source DB:  PubMed          Journal:  Malawi Med J        ISSN: 1995-7262            Impact factor:   0.875


  44 in total

1.  Reinfection, exposure and immunity in human schistosomiasis.

Authors:  P Hagan
Journal:  Parasitol Today       Date:  1992-01

Review 2.  Antischistosomal drugs: past, present ... and future?

Authors:  D Cioli; L Pica-Mattoccia; S Archer
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

3.  Immune responses and immunoregulation in relation to human schistosomiasis in Egypt. III. Immunity and longitudinal studies of in vitro responsiveness after treatment.

Authors:  D G Colley; I S Barsoum; H S Dahawi; F Gamil; M Habib; M A el Alamy
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

4.  Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection.

Authors:  D W Dunne; A E Butterworth; A J Fulford; H C Kariuki; J G Langley; J H Ouma; A Capron; R J Pierce; R F Sturrock
Journal:  Eur J Immunol       Date:  1992-06       Impact factor: 5.532

5.  IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis.

Authors:  De'Broski R Herbert; Tatyana Orekov; Charles Perkins; Fred D Finkelman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

6.  Hepatosplenomegaly is associated with low regulatory and Th2 responses to schistosome antigens in childhood schistosomiasis and malaria coinfection.

Authors:  Shona Wilson; Frances M Jones; Joseph K Mwatha; Gachuhi Kimani; Mark Booth; H Curtis Kariuki; Birgitte J Vennervald; John H Ouma; Eric Muchiri; David W Dunne
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

7.  Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium.

Authors:  P Hagan; U J Blumenthal; D Dunn; A J Simpson; H A Wilkins
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

8.  Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens.

Authors:  Joelma R de Souza; Clarice N L Morais; Marcílio L Aroucha; Paulo J C Miranda; Constança S Barbosa; Ana Lúcia C Domingues; Luiz B Carvalho Júnior; Frederico G C Abath; Silvia M L Montenegro
Journal:  Mem Inst Oswaldo Cruz       Date:  2007-05       Impact factor: 2.743

9.  Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.

Authors:  A E Butterworth; M Capron; J S Cordingley; P R Dalton; D W Dunne; H C Kariuki; G Kimani; D Koech; M Mugambi; J H Ouma
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

10.  Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Sophy Ngom-Wegi; Juliet Ndibazza; Trinh Duong; Birgitte J Vennervald; David W Dunne; Eli Katunguka-Rwakishaya; Alison M Elliott
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

View more
  3 in total

1.  Drug treatment of malaria infections can reduce levels of protection transferred to offspring via maternal immunity.

Authors:  Vincent Staszewski; Sarah E Reece; Aidan J O'Donnell; Emma J A Cunningham
Journal:  Proc Biol Sci       Date:  2012-02-22       Impact factor: 5.349

2.  Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.

Authors:  Mark S Pearson; Luke Becker; Patrick Driguez; Neil D Young; Soraya Gaze; Tiago Mendes; Xiao-Hong Li; Denise L Doolan; Nicholas Midzi; Takafira Mduluza; Donald P McManus; R Alan Wilson; Jeffrey M Bethony; Norman Nausch; Francisca Mutapi; Philip L Felgner; Alex Loukas
Journal:  Front Immunol       Date:  2015-05-05       Impact factor: 7.561

3.  Study participants incentives, compensation and reimbursement in resource-constrained settings.

Authors:  Takafira Mduluza; Nicholas Midzi; Donold Duruza; Paul Ndebele
Journal:  BMC Med Ethics       Date:  2013-12-19       Impact factor: 2.652

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.